Full history for every metric is available with a Kvantra account
Enzo Biochem, Inc. (ENZ)
Key financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Total revenue | $m | 81 | 76 | 118 | 107 | 31 | 32 | 27 |
| Operating profit | $m | -10 | -11 | |||||
| Net profit | $m | -99 | -34 | 3 | -23 | 20 | -26 | -21 |
| EPS reported | $ | -0.51 | -0.40 | |||||
| Operating cashflow per share | $ | -0.52 | -0.52 | |||||
| Capex per share | $ | 0.01 | 0.01 | |||||
| FCF per share | $ | -0.53 | -0.53 | |||||
| Free cash flow | $m | -27 | -16 | |||||
| Net debt | $m | -52 | -36 | |||||
| Book value equity | $m | 56 | 43 | |||||
| Book value per share | $ | 1.10 | 0.83 | |||||
| Number of shares | m | 50.9 | 52.4 | |||||
| DPS (TTM paid) | $ | 0.10 | 0.10 |
Financial summary
Financials in USD| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | TTM | ||
|---|---|---|---|---|---|---|---|---|
| Value | ||||||||
| P/E TTM | x | - | - | |||||
| P/B LTM | x | 1.03 | 0.38 | |||||
| P/S LTM | x | 1.82 | 0.60 | |||||
| P/FCF LTM | x | -2.16 | -1.01 | |||||
| EV/EBITDA LTM | x | -1.10 | 2.98 | |||||
| EV/Sales LTM | x | 0.29 | -0.73 | |||||
| Earnings Yield LTM | % | -44.94% | -163.26% | |||||
| FCF Yield | % | -46.19% | -99.42% | |||||
| Quality | ||||||||
| ROE | % | -46.47% | -38.76% | |||||
| ROIC | % | -15.86% | -15.86% | |||||
| Operating margin | % | -30.77% | -30.77% | |||||
| Gross margin | % | 45.86% | 45.86% | |||||
| FCF/Sales | % | -84.01% | -84.01% | |||||
| Growth and momentum | ||||||||
| EPS Growth YoY | % | - | - | |||||
| Sales Growth YoY | % | +2.72% | +481.97% | |||||
| Net Income Growth YoY | % | - | - | |||||
| FCF Growth | % | - | - | |||||
| Operating Profit Growth | % | - | - | |||||
| Dividend and capital structure | ||||||||
| Dividend Yield | % | 0.00% | 31.87% | |||||
| Dividend Growth | % | - | - | |||||
| Payout Ratio | % | 0.00% | -50.40% | |||||
| FCF/Debt | x | -7.64 | -5.44 | |||||
| Net Debt/EBITDA | x | 5.85 | 5.85 | |||||
| EBIT/Net interest | x | -49.83 | -49.83 | |||||
| Net debt/market cap | % | -89.79% | -221.91% | |||||
| Net debt/Equity | x | -0.93 | -0.84 | |||||
| Gross debt/equity | x | 0.06 | 0.07 | |||||
Company overview
Enzo Biochem, Inc. is a diversified enterprise that encompasses diagnostics, clinical laboratory services, and life sciences. The company's core activities involve the entire process of researching, developing, manufacturing, and commercializing diagnostic and scientific investigation products, drawing upon advancements in genetic engineering, biotechnology, and molecular biology. Its operations are organized into three primary segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products division is responsible for creating, producing, and distributing vital tools and reagents tailored for customers in clinical research, pharmaceutical development, and broader bioscience research. Its extensive product catalog features items such as proteins, antibodies, peptides, small molecules, labeling agents, dyes, and various kits. These offerings provide life science researchers with the means for target identification and validation, content analysis, gene expression studies, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also supplies specialized solutions to scientific experts investigating critical health areas, including cancer, cardiovascular ailments, neurological disorders, metabolic conditions (like diabetes and obesity), endocrine imbalances, infectious and autoimmune diseases, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment delivers a comprehensive spectrum of molecular and other clinical laboratory tests and procedures. These are utilized by physicians in routine patient care to help confirm or establish diagnoses, monitor the effectiveness of treatments or medications, and identify previously undiagnosed medical conditions. This division operates a central, full-service clinical laboratory in Farmingdale, New York, complemented by a network of 30 patient service centers across New York and New Jersey. Additionally, it runs dedicated "STAT" or rapid-response laboratories in New York City and Connecticut, alongside a full-service phlebotomy facility and an internal logistics department. The Therapeutics segment is dedicated to pioneering novel treatment approaches within the fields of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem distributes its array of products and services through its dedicated internal sales team and an extensive network of distributors, reaching both domestic and international markets. The company was established in 1976 and has its corporate headquarters situated in New York, New York.
Similar companies
For informational purposes only. Kvantra provides data and quantitative analysis, not investment advice. KvantraRank is a mechanical model output. Analyst price targets and ratings are sourced from third parties and are not Kvantra recommendations. Past performance does not guarantee future results; all investments carry risk.
Enzo Biochem, Inc. (ENZ)
Enzo Biochem, Inc. is a diversified enterprise that encompasses diagnostics, clinical laboratory services, and life sciences. The company's core activities involve the entire process of researching, developing, manufacturing, and commercializing diagnostic and scientific investigation products, drawing upon advancements in genetic engineering, biotechnology, and molecular biology. Its operations are organized into three primary segments: Life Sciences Products, Clinical Laboratory Services, and Therapeutics. The Life Sciences Products division is responsible for creating, producing, and distributing vital tools and reagents tailored for customers in clinical research, pharmaceutical development, and broader bioscience research. Its extensive product catalog features items such as proteins, antibodies, peptides, small molecules, labeling agents, dyes, and various kits. These offerings provide life science researchers with the means for target identification and validation, content analysis, gene expression studies, nucleic acid detection, protein biochemistry and detection, and cellular analysis. This segment also supplies specialized solutions to scientific experts investigating critical health areas, including cancer, cardiovascular ailments, neurological disorders, metabolic conditions (like diabetes and obesity), endocrine imbalances, infectious and autoimmune diseases, hepatotoxicity, and renal injury. The Clinical Laboratory Services segment delivers a comprehensive spectrum of molecular and other clinical laboratory tests and procedures. These are utilized by physicians in routine patient care to help confirm or establish diagnoses, monitor the effectiveness of treatments or medications, and identify previously undiagnosed medical conditions. This division operates a central, full-service clinical laboratory in Farmingdale, New York, complemented by a network of 30 patient service centers across New York and New Jersey. Additionally, it runs dedicated "STAT" or rapid-response laboratories in New York City and Connecticut, alongside a full-service phlebotomy facility and an internal logistics department. The Therapeutics segment is dedicated to pioneering novel treatment approaches within the fields of gastrointestinal, infectious, ophthalmic, and metabolic diseases. Enzo Biochem distributes its array of products and services through its dedicated internal sales team and an extensive network of distributors, reaching both domestic and international markets. The company was established in 1976 and has its corporate headquarters situated in New York, New York.
Unlock all fundamental data
Sign up for FreeUnlock all fundamental data
Sign up for Free